Privia Health Group, Inc. (PRVA)

Over the past six months, Privia Health Group, Inc.'s stock (PRVA) has experienced various movements, with a 52-week range between $18.77 and $26.51. As of April 11, 2026, the stock moved 7.1% over the last 7 days and 1.1% over the past month. Key events impacting the stock include the report of Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026, which saw the stock price increase by 9.98%. On March 3, 2026, the company announced its program achieved an 84% colorectal cancer screening rate, which was followed by a slight stock decrease of 1.12%. News of CFO David Mountcastle selling shares and subsequent analyst updates put the stock in focus on April 8, 2026. On April 10, 2026, the stock price was noted to be falling, with a pre-market move of -3.06%. Privia Health is scheduled to report its First Quarter 2026 results on May 7, 2026.

The provided search results do not explicitly detail specific demand seasonality for Privia Health Group, Inc.'s products and services. However, as a physician enablement company involved in healthcare services and value-based care arrangements, demand for its services may be influenced by factors common in the healthcare industry, such as annual enrollment periods for health plans, flu seasons, and other cyclical health trends.

Privia Health Group, Inc. is a technology-driven national physician-enablement company that collaborates with medical groups, health plans, and health systems to enhance physician practices and improve patient experiences. The company focuses on optimizing physician practices, improving patient experiences, and rewarding doctors for delivering high-value care in both in-person and virtual settings. Its core offering is the Privia Platform, an extensive suite of technology and service solutions designed to support population health, practice operations, and value-based care performance. The company builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, and a physician-led governance structure. Key services include management services through local MSOs, a single-TIN medical group for negotiating power and clinical integration, and ACOs that engage patients, reduce inappropriate utilization, and enhance care coordination. Privia Health participates in various value-based care arrangements, including MSSP, Medicare Advantage, commercial, and Medicaid programs.

Privia Health Group, Inc. has a significant presence across the United States, operating in approximately 24 states and the District of Columbia. The company's headquarters are located in Arlington, Virginia. A substantial portion of its revenue is driven by medical practices in states such as Virginia, Maryland, the District of Columbia, Texas, Tennessee, Florida, and Georgia. As of April 2024, Privia Health has expanded its footprint to over 1,000 practice locations, serving more than 4.7 million patients.

In the past year, Privia Health Group has demonstrated a positive brand reputation through its achievements and strategic expansions. In March 2026, the company's program achieved an 84% colorectal cancer screening rate through industry collaboration. In April 2026, Privia Health earned the 2026 HFMA MAP Award for Revenue Cycle Excellence. In September 2025, Privia Health announced the acquisition of an ACO business from Evolent Health, expanding its value-based care footprint and attributed lives.

Privia Health Group, Inc. is primarily owned by institutional shareholders, who hold approximately 97.64% of the stock. Major institutional owners include BlackRock, Inc., Durable Capital Partners LP, Fmr Llc, Vanguard Group Inc, Rubicon Founders LLC, Riverbridge Partners Llc, State Street Corp, Van Berkom & Associates Inc., Bank of New York Mellon Corp, and Geode Capital Management, Llc. Pamplona Capital Management LLC is noted as the largest individual shareholder, owning 77.52% of the company's shares. Insiders own about 2.11% of the stock, while public companies and individual investors hold approximately 15.38%.